Review



primary antibody against collagen type 3  (Novus Biologicals)


Bioz Verified Symbol Novus Biologicals is a verified supplier
Bioz Manufacturer Symbol Novus Biologicals manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    Novus Biologicals primary antibody against collagen type 3
    Primary Antibody Against Collagen Type 3, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 95/100, based on 45 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibody against collagen type 3/product/Novus Biologicals
    Average 95 stars, based on 45 article reviews
    primary antibody against collagen type 3 - by Bioz Stars, 2026-06
    95/100 stars

    Images



    Similar Products

    collagen iii alpha 1/col3a1 antibody (1e7-d7/col3) - bsa free  (Bio-Techne corporation)
    94
    Bio-Techne corporation collagen iii alpha 1/col3a1 antibody (1e7-d7/col3) - bsa free
    Collagen Iii Alpha 1/Col3a1 Antibody (1e7 D7/Col3) Bsa Free, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/collagen iii alpha 1/col3a1 antibody (1e7-d7/col3) - bsa free/product/Bio-Techne corporation
    Average 94 stars, based on 1 article reviews
    collagen iii alpha 1/col3a1 antibody (1e7-d7/col3) - bsa free - by Bioz Stars, 2026-06
    94/100 stars
    		  Buy from Supplier
    primary antibody against collagen type 3  (Novus Biologicals)
    95
    Novus Biologicals primary antibody against collagen type 3
    Primary Antibody Against Collagen Type 3, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibody against collagen type 3/product/Novus Biologicals
    Average 95 stars, based on 1 article reviews
    primary antibody against collagen type 3 - by Bioz Stars, 2026-06
    95/100 stars
    		  Buy from Supplier
    primary antibodies against col3a1  (Proteintech)
    96
    Proteintech primary antibodies against col3a1
    Fig. 3 Matrix stiffness mediated by CAFs is closely associated with HCC. (A) Clustering results for aneuploid and euploid samples. The ordinate represents cells, and the abscissa represents chromosome positions. Orange indicates an increase in DNA copy number, while blue indicates a decrease in DNA copy number. (B) The distribution of tumor cells and non-tumor cells after reordering. (C) UMAP visualization of the positional distribution of tumor cells and non-tumor cells. (D) The proportion of tumor cells and non-tumor cells in CAFs across different clusters. (E) The proportion of CAFs from different clusters within tumor cells and non-tumor cells. (F-I) The expression level of COL1A1, COL1A2, <t>COL3A1</t> and LOX in CAFs from different clusters. (J-M) Violin plot of COL1A1, COL1A2, COL3A1 and LOX expression in tumor tissues, normal tissues, PVTT, and lymph node tissues corresponding to cluster2-CAFs
    Primary Antibodies Against Col3a1, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against col3a1/product/Proteintech
    Average 96 stars, based on 1 article reviews
    primary antibodies against col3a1 - by Bioz Stars, 2026-06
    96/100 stars
    		  Buy from Supplier
    anti type iii collagen primary antibody  (Novus Biologicals)
    93
    Novus Biologicals anti type iii collagen primary antibody
    Immunohistochemical analysis of the lesions. (a) Immunohistochemical staining for type <t>I</t> <t>collagen</t> on day 17 in the NC and the different treatments. Magnification: 400x. Scale bar: 50 μm. (b) Immunohistochemical staining for type <t>III</t> collagen on day 17 in the NC and the different treatments.
    Anti Type Iii Collagen Primary Antibody, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti type iii collagen primary antibody/product/Novus Biologicals
    Average 93 stars, based on 1 article reviews
    anti type iii collagen primary antibody - by Bioz Stars, 2026-06
    93/100 stars
    		  Buy from Supplier
    anticol3a1 primary antibodies  (Proteintech)
    96
    Proteintech anticol3a1 primary antibodies
    Immunohistochemical analysis of the lesions. (a) Immunohistochemical staining for type <t>I</t> <t>collagen</t> on day 17 in the NC and the different treatments. Magnification: 400x. Scale bar: 50 μm. (b) Immunohistochemical staining for type <t>III</t> collagen on day 17 in the NC and the different treatments.
    Anticol3a1 Primary Antibodies, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anticol3a1 primary antibodies/product/Proteintech
    Average 96 stars, based on 1 article reviews
    anticol3a1 primary antibodies - by Bioz Stars, 2026-06
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    Fig. 3 Matrix stiffness mediated by CAFs is closely associated with HCC. (A) Clustering results for aneuploid and euploid samples. The ordinate represents cells, and the abscissa represents chromosome positions. Orange indicates an increase in DNA copy number, while blue indicates a decrease in DNA copy number. (B) The distribution of tumor cells and non-tumor cells after reordering. (C) UMAP visualization of the positional distribution of tumor cells and non-tumor cells. (D) The proportion of tumor cells and non-tumor cells in CAFs across different clusters. (E) The proportion of CAFs from different clusters within tumor cells and non-tumor cells. (F-I) The expression level of COL1A1, COL1A2, COL3A1 and LOX in CAFs from different clusters. (J-M) Violin plot of COL1A1, COL1A2, COL3A1 and LOX expression in tumor tissues, normal tissues, PVTT, and lymph node tissues corresponding to cluster2-CAFs

    Journal: Journal of translational medicine

    Article Title: CAFs activated by YAP1 upregulate cancer matrix stiffness to mediate hepatocellular carcinoma progression.

    doi: 10.1186/s12967-025-06325-5

    Figure Lengend Snippet: Fig. 3 Matrix stiffness mediated by CAFs is closely associated with HCC. (A) Clustering results for aneuploid and euploid samples. The ordinate represents cells, and the abscissa represents chromosome positions. Orange indicates an increase in DNA copy number, while blue indicates a decrease in DNA copy number. (B) The distribution of tumor cells and non-tumor cells after reordering. (C) UMAP visualization of the positional distribution of tumor cells and non-tumor cells. (D) The proportion of tumor cells and non-tumor cells in CAFs across different clusters. (E) The proportion of CAFs from different clusters within tumor cells and non-tumor cells. (F-I) The expression level of COL1A1, COL1A2, COL3A1 and LOX in CAFs from different clusters. (J-M) Violin plot of COL1A1, COL1A2, COL3A1 and LOX expression in tumor tissues, normal tissues, PVTT, and lymph node tissues corresponding to cluster2-CAFs

    Article Snippet: Primary antibodies against COL3A1 (Proteintech, cat.22734-1-AP, 1:1000), YAP1 (Proteintech, cat.135841-AP, 1:3000), COL1A1 (Immunoway, cat. YM 4807, 1:1000), COL1A2 (Immunoway, cat.YT1019, 1:1000), LOX (Immunoway, cat. YN 4611, 1:1000) and GAPDH (Proteintech, cat. No. 60004-1-Ig, 1:50,000) were used for Western blotting.

    Techniques: Expressing

    Fig. 4 High matrix stiffness is negatively correlated with the prognosis of HCC patients. (A-D) Expression levels of COL1A1, COL1A2, COL3A1 and LOX in cancer and normal liver tissues. (E-H) Survival curve for HCC patients with different expression levels of COL1A1, COL1A2, COL3A1 and LOX. * P<0.05

    Journal: Journal of translational medicine

    Article Title: CAFs activated by YAP1 upregulate cancer matrix stiffness to mediate hepatocellular carcinoma progression.

    doi: 10.1186/s12967-025-06325-5

    Figure Lengend Snippet: Fig. 4 High matrix stiffness is negatively correlated with the prognosis of HCC patients. (A-D) Expression levels of COL1A1, COL1A2, COL3A1 and LOX in cancer and normal liver tissues. (E-H) Survival curve for HCC patients with different expression levels of COL1A1, COL1A2, COL3A1 and LOX. * P<0.05

    Article Snippet: Primary antibodies against COL3A1 (Proteintech, cat.22734-1-AP, 1:1000), YAP1 (Proteintech, cat.135841-AP, 1:3000), COL1A1 (Immunoway, cat. YM 4807, 1:1000), COL1A2 (Immunoway, cat.YT1019, 1:1000), LOX (Immunoway, cat. YN 4611, 1:1000) and GAPDH (Proteintech, cat. No. 60004-1-Ig, 1:50,000) were used for Western blotting.

    Techniques: Expressing

    Fig. 9 Verification of cell experiments and animal experiments. (A, B) Tumor volume and Tumor weight distribution maps of the control group, Vertepor fin treatment group and K-975 treatment group. (C-H) The mRNA and protein expression levels of YAP1, COL1A1, COL1A2, COL3A1, and LOX were analyzed in CAFs from the control group, the group treated with Verteporfin, and the group treated with K-975. (I, J) The concentrations of COL1A1 and COL1A2 in the supernatants of CAFs from the control group and the K-975 treatment group were measured. * P<0.05, **P<0.01, ***P<0.001

    Journal: Journal of translational medicine

    Article Title: CAFs activated by YAP1 upregulate cancer matrix stiffness to mediate hepatocellular carcinoma progression.

    doi: 10.1186/s12967-025-06325-5

    Figure Lengend Snippet: Fig. 9 Verification of cell experiments and animal experiments. (A, B) Tumor volume and Tumor weight distribution maps of the control group, Vertepor fin treatment group and K-975 treatment group. (C-H) The mRNA and protein expression levels of YAP1, COL1A1, COL1A2, COL3A1, and LOX were analyzed in CAFs from the control group, the group treated with Verteporfin, and the group treated with K-975. (I, J) The concentrations of COL1A1 and COL1A2 in the supernatants of CAFs from the control group and the K-975 treatment group were measured. * P<0.05, **P<0.01, ***P<0.001

    Article Snippet: Primary antibodies against COL3A1 (Proteintech, cat.22734-1-AP, 1:1000), YAP1 (Proteintech, cat.135841-AP, 1:3000), COL1A1 (Immunoway, cat. YM 4807, 1:1000), COL1A2 (Immunoway, cat.YT1019, 1:1000), LOX (Immunoway, cat. YN 4611, 1:1000) and GAPDH (Proteintech, cat. No. 60004-1-Ig, 1:50,000) were used for Western blotting.

    Techniques: Control, Expressing

    Immunohistochemical analysis of the lesions. (a) Immunohistochemical staining for type I collagen on day 17 in the NC and the different treatments. Magnification: 400x. Scale bar: 50 μm. (b) Immunohistochemical staining for type III collagen on day 17 in the NC and the different treatments.

    Journal: Acta Cirúrgica Brasileira

    Article Title: Type I and type III collagen immunoexpression in rabbit skin biopsy samples treated with rosuvastatin gel and autologous platelet-rich plasma

    doi: 10.1590/acb402725

    Figure Lengend Snippet: Immunohistochemical analysis of the lesions. (a) Immunohistochemical staining for type I collagen on day 17 in the NC and the different treatments. Magnification: 400x. Scale bar: 50 μm. (b) Immunohistochemical staining for type III collagen on day 17 in the NC and the different treatments.

    Article Snippet: Antibodies for evaluating collagen immunoexpression in rabbit wounds treated with aPRP, RSV, and aPRP + RSV included: anti-type I collagen primary antibody (1:50, mouse monoclonal, GeneTex, GTX26308), anti-type III collagen primary antibody (1:100, mouse monoclonal, Novus Biologicals, NBP1-05119), and goat anti-mouse IgG H&L (HRP) antibody (1:200, goat, Abcam, ab6789).

    Techniques: Immunohistochemical staining, Staining

    Plots representing the average percentage of immunostaining for types I and III collagen under different treatments on day 17.

    Journal: Acta Cirúrgica Brasileira

    Article Title: Type I and type III collagen immunoexpression in rabbit skin biopsy samples treated with rosuvastatin gel and autologous platelet-rich plasma

    doi: 10.1590/acb402725

    Figure Lengend Snippet: Plots representing the average percentage of immunostaining for types I and III collagen under different treatments on day 17.

    Article Snippet: Antibodies for evaluating collagen immunoexpression in rabbit wounds treated with aPRP, RSV, and aPRP + RSV included: anti-type I collagen primary antibody (1:50, mouse monoclonal, GeneTex, GTX26308), anti-type III collagen primary antibody (1:100, mouse monoclonal, Novus Biologicals, NBP1-05119), and goat anti-mouse IgG H&L (HRP) antibody (1:200, goat, Abcam, ab6789).

    Techniques: Immunostaining